Dr Wagner notes the paucity of secondary prevention data and virtual lack of primary prevention data concerning cholesterol lowering with statin drugs in women. While awaiting the accumulation of direct data from trials,1 we believe the overall results rather than sex-specific subgroup analyses provide the most reliable estimates of treatment effects.2 Further, in the large-scale secondary prevention trials, there do not appear to be qualitative differences in treatment effects between men and women. Thus, it would be unusual to find qualitative differences between men and women in cardiovascular disease benefits in the ongoing primary prevention trials.
Hebert P, Chan KS, Gaziano JM, Hennekens CH. Cholesterol Lowering With Statin Drugs: Evidence in Women-Reply. JAMA. 1997;278(20):1660-1661. doi:10.1001/jama.1997.03550200036025